American Association for Cancer Research

Skip to Main Content

Table 2

Summary of type and length of response to TM therapy

	No. of patients (Total = 18)	Duration in days of copper deficiency (average)
Type of response
Did not achieve target Cp	4
Achieved target Cp	14
Target Cp <90 days	8/14
Disease progression	7
Stable disease with partial regression of lung lesions	1	49^a
Target Cp >90 days	6/14
Stable disease with partial regression of lung lesions	1/6	120^a
Stable disease	4/6	159^b, 329^a, 351^a, 413^a (313^a)
Disease progression at one site, stable elsewhere	1/6	120^a

	No. of patients (Total = 18)	Duration in days of copper deficiency (average)
Type of response
Did not achieve target Cp	4
Achieved target Cp	14
Target Cp <90 days	8/14
Disease progression	7
Stable disease with partial regression of lung lesions	1	49^a
Target Cp >90 days	6/14
Stable disease with partial regression of lung lesions	1/6	120^a
Stable disease	4/6	159^b, 329^a, 351^a, 413^a (313^a)
Disease progression at one site, stable elsewhere	1/6	120^a

^a

On therapy.

^b

Patient discontinued therapy.